Tumor-Derived GDF15 Induces CCN3+ Schwann Cells to Promote Cancer Pain in Pancreatic Cancer
A recent study published in Nature Communications elucidates the mechanism behind chronic pain in pancreatic ductal adenocarcinoma (PDAC). Researchers identified that tumor-derived growth differentiation factor 15 (GDF15) drives the expansion of a specialized subpopulation of CCN3-positive Schwann cells. This process occurs through the activation of the GFRAL receptor, which triggers the AKT-RUNX2 signaling cascade and upregulates the glycolytic enzyme PFKM, leading to metabolic reprogramming in these cells. The resulting glycolytic changes enhance tumor innervation and sensitize sensory nerves, thereby contributing significantly to cancer-associated pain. Crucially, the study demonstrates that targeted inhibition of the GDF15-GFRAL signaling pathway in CCN3+ Schwann cells effectively alleviates pain in PDAC models. These findings reveal a critical perineural-metabolic axis involving glial networks and offer a promising therapeutic strategy for managing severe pain in pancreatic cancer patients, addressing a major clinical challenge in oncology and neuroscience.
Wire timeline
Tumor-Derived GDF15 Induces CCN3+ Schwann Cells to Promote Cancer Pain in Pancreatic Cancer
A recent study published in Nature Communications elucidates the mechanism behind chronic pain in pancreatic ductal adenocarcinoma (PDAC). Researchers identified that tumor-derived growth differentiation factor 15 (GDF15) drives the expansion of a specialized subpopulation of CCN3-positive Schwann cells. This process occurs through the activation of the GFRAL receptor, which triggers the AKT-RUNX2 signaling cascade and upregulates the glycolytic enzyme PFKM, leading to metabolic reprogramming in these cells. The resulting glycolytic changes enhance tumor innervation and sensitize sensory nerves, thereby contributing significantly to cancer-associated pain. Crucially, the study demonstrates that targeted inhibition of the GDF15-GFRAL signaling pathway in CCN3+ Schwann cells effectively alleviates pain in PDAC models. These findings reveal a critical perineural-metabolic axis involving glial networks and offer a promising therapeutic strategy for managing severe pain in pancreatic cancer patients, addressing a major clinical challenge in oncology and neuroscience.
Nature Communications